Researchers are evaluating GLP-1 receptor agonist drugs for the treatment of various chronic diseases, including several types of cancer [2].

This expansion of research matters because these medications, originally designed for diabetes and obesity, may address a broad spectrum of conditions linked to metabolic dysfunction. By modulating appetite, glucose metabolism, and inflammatory pathways, these drugs could transform the management of systemic health [1, 3].

Ongoing studies are investigating the drugs' efficacy against cardiovascular disease, kidney disease, and sleep apnea [3]. Other areas of focus include endometriosis, and symptoms associated with menopause [3]. A key study regarding the risk of cancer progression is being presented this week at the American Society of Clinical Oncology annual meeting in the U.S. [2, 4].

More than 400 clinical trials are currently investigating GLP-1 drugs for various conditions [1]. Experts said seven distinct conditions beyond weight loss are potential treatment targets for these therapies [3].

Despite the clinical potential, patient adherence remains a significant hurdle. Data suggests that up to 60% of patients discontinue GLP-1 therapy within the first year [5]. This attrition rate poses a challenge for clinicians attempting to manage long-term chronic illnesses.

Pharmaceutical companies and clinicians continue to conduct these trials worldwide to determine if the metabolic benefits of semaglutide and tirzepatide can be replicated across different disease states [1, 2].

“More than 400 clinical trials are investigating GLP-1 drugs for various conditions.”

The shift toward using GLP-1 agonists for non-metabolic conditions suggests a move toward 'pleiotropic' medicine, where one drug treats multiple unrelated systems. If these trials prove successful, it could shift the standard of care for oncology and cardiology, though the high discontinuation rate indicates that the long-term viability of these treatments depends on improving patient tolerance and accessibility.